(Q40626125)

22 September 2017

1 reference

title

Management of antiretroviral drug therapy in human immunodeficiency virus infection (English)

1 reference

22 September 2017

Stretcher B

1

1 reference

22 September 2017

publication date

1 January 1994

1 reference

Critical Reviews in Clinical Laboratory Sciences

22 September 2017

published in

1 reference

22 September 2017

volume

31

1 reference

22 September 2017

issue

2

1 reference

22 September 2017

page(s)

169-196

1 reference

The molecular biology of human immunodeficiency virus type 1 infection

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Nucleosides. V. The Monomesylates of 1-(2'-Deoxy-β-D-lyxofuranosyl)thymine1,2

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Clinical pharmacokinetics of zidovudine. An overview of current data

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Zidovudine: five years later

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Comparative pharmacokinetics of antiviral nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Pharmacokinetics of zidovudine in patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudi

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Clinical pharmacokinetics of 3'-azido-3'-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3'-amino-3'-deoxythymidine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Pharmacokinetics of 3'-azido-3'-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Effects of granulocyte-macrophage colony-stimulating factor on 3'-azido-3'-deoxythymidine uptake, phosphorylation and nucleotide retention in human U-937 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Effects of thymidine and uridine on the phosphorylation of 3'-azido-3'-deoxythymidine (zidovudine) in human mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Intracellular metabolism of 3'-azidothymidine in isolated human peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Antiretroviral therapy: reverse transcriptase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Therapy for human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Neopterin and β2-microglobulin as prognostic indices in human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Nail dyschromia associated with zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Zidovudine-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Zidovudine toxicity. Clinical features and management

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

A pilot study of low-dose zidovudine in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

A randomized trial of reduced doses of azidothymidine in Japanese patients with human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Zidovudine dosage. Nordic Medical Research Councils' HIV Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Acetaminophen does not impair clearance of zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Dideoxyinosine in Children with Symptomatic Human Immunodeficiency Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Randomized study of two doses of didanosine in children infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Detection of Mutations Associated with Zidovudine Resistance in Human Immunodeficiency Virus by Use of the Polymerase Chain Reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Serum beta 2-microglobulin and prediction of progression to AIDS in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Acquired immunodeficiency syndrome. Cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Pharmacokinetic optimisation of anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369409084676

10.3109/10408369409084676

21 January 2018

Identifiers

DOI

1 reference

22 September 2017

1 reference